Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WHO Does What It Warned: Delists Shantha Biotech's Pentavalent Vaccine Shan5; More Pains For Sanofi-Aventis?

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - In a move that could in the short term severely impair the reputation of Hyderabad-based vaccines maker Shantha Biotechnics, now part of Sanofi-Aventis, the World Health Organization has delisted its popular pentavalent vaccine Shan5, which is used by scores of nations as part of their national immunization programs for the prevention against deadly diseases like diphtheria, tetanus, hepatitis B and Hib

You may also be interested in...



No Cease-Fire: India Seeks $190 Million Tax From Sanofi’s Shantha Deal

India’s tax department has filed a petition with the Supreme Court, challenging an earlier judgment that sided with Sanofi in a tax dispute that could impact future acquisitions in the country.

No Cease Fire: India Seeks $190 Million Tax From Sanofi’s Shantha Deal

India’s tax department has filed a petition with the Supreme Court, challenging an earlier judgment that sided with Sanofi in a tax dispute that could impact future acquisitions in the country.

WHO Nod To India’s Regulatory System A Booster For Vaccine Makers

Indian vaccine makers see the latest move to qualify the Indian regulatory system as an opportunity to pump up exports.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC075781

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel